Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex

Blood

Volumn 121, Issue 23, 2013, Pages 4729-4739

  Wise, Jillian F ^a,b   Berkova, Zuzana ^a   Mathur, Rohit ^a   Zhu, Haifeng ^a   Braun, Frank K ^a   Tao, Rong Hua ^a   Sabichi, Anita L ^c   Ao, Xue ^a   Maeng, Hoyoung ^a   Samaniego, Felipe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; NUCLEOLIN; MESSENGER RNA; PHOSPHOPROTEIN; RNA BINDING PROTEIN;

ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B CELL LYMPHOMA CELL; B LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LIVER CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RNA-BINDING DOMAIN; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CELL MEMBRANE; CELL PROLIFERATION; FLOW CYTOMETRY; GENETICS; IMMUNOPRECIPITATION; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL MEMBRANE; CELL PROLIFERATION; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PHOSPHOPROTEINS; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 84881054800     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-471094     Document Type: Article

References (61)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4): 212-236.
2. Kondo E, Yoshino T. Expression of apoptosis regulators in germinal centers and germinal center-derived B-cell lymphomas: insight into B-cell lymphomagenesis. Pathol Int. 2007;57(7): 391-397.
3. Timmer T, de Vries EG, de Jong S. Fas receptormediated apoptosis: a clinical application? J Pathol. 2002;196(2):125-134.
4. Lynch DH, Watson ML, Alderson MR, et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1994;1(2):131-136.
5. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995; 268(5215):1347-1349.
6. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2(5):574-577.
7. Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive-and drug-resistant tumor cells. Cell Death Differ. 1999;6(5):471-480.
8. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia. 1999;13(11): 1854-1858.
9. Eichhorst ST, Müerköster S, Weigand MA, Krammer PH. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res. 2001;61(1): 243-248.
10. Müller M, Scaffidi CA, Galle PR, Stremmel W, Krammer PH. The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapyinduced apoptosis. Eur Cytokine Netw. 1998;9(4): 685-686.
11. Poulaki V, Mitsiades CS, Mitsiades N. The role of Fas and FasL as mediators of anticancer chemotherapy. Drug Resist Updat. 2001;4(4):233-242.
12. Gajate C, Del Canto-Jañez E, Acuña AU, et al. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fasenriched rafts in selective tumor cell apoptosis. J Exp Med. 2004;200(3):353-365.
13. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - inducing signaling complex. Cell. 1996; 85(6):817-827.
14. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326(Pt 1):1-16.
15. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia. 1997;11(11):1833-1841.
16. Berkova Z, Wang S, Wise JF, Maeng H, Ji Y, Samaniego F. Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein. J Natl Cancer Inst. 2009;101(6):399-411.
17. Wang S, Wang S, Maeng H, et al. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fasmediated apoptosis. Blood. 2007;109(5):2174-2182.
18. Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J. 1999;13(14):1911-1922.
19. Ridley L, Rahman R, Brundler MA, et al; Children's Cancer and Leukaemia Group Biological Studies Committee. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro-oncol. 2008; 10(5):675-689.
20. Hovanessian AG, Puvion-Dutilleul F, Nisole S, et al. The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res. 2000;261(2):312-328.
21. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol. 2003; 163(4):871-878.
22. Said EA, Courty J, Svab J, Delbé J, Krust B, Hovanessian AG. Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin. FEBS J. 2005;272(18):4646-4659.
23. Reyes-Reyes EM, Akiyama SK. Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cells. Exp Cell Res. 2008;314(11-12):2212-2223.
24. Otake Y, Soundararajan S, Sengupta TK, et al. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood. 2007;109(7):3069-3075.
25. Chen CY, Gherzi R, Andersen JS, et al. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev. 2000;14(10):1236-1248.
26. Tate A, Isotani S, Bradley MJ, et al. Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer. 2006;6:197.
27. Pasternack MS, Bleier KJ, McInerney TN. Granzyme A binding to target cell proteins. Granzyme A binds to and cleaves nucleolin in vitro. J Biol Chem. 1991;266(22):14703-14708.
28. Mi Y, Thomas SD, Xu X, Casson LK, Miller DM, Bates PJ. Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. J Biol Chem. 2003; 278(10):8572-8579.
29. Tao RH, Berkova Z, Wise JF, et al. PMLRARa binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood. 2011;118(11):3107-3118.
30. Braun FK, Al-Yacoub N, Plötz M, Möbs M, Sterry W, Eberle J. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand. J Invest Dermatol. 2012;132(2):429-439.
31. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6(7):1258-1266.
32. Shatnyeva OM, Kubarenko AV, Weber CE, et al. Modulation of the CD95-induced apoptosis: the role of CD95 N-glycosylation. PLoS ONE. 2011; 6(5):e19927.
33. Keppler OT, Peter ME, Hinderlich S, et al. Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Glycobiology. 1999;9(6):557-569.
34. Schuchmann M, Varfolomeev EE, Hermann F, et al. Dominant negative MORT1/FADD rescues mice from CD95 and TNF-induced liver failure. Hepatology. 2003;37(1):129-135.
35. Shi H, Huang Y, Zhou H, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood. 2007; 110(8):2899-2906.
36. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med. 2011;17(9):1132-1135.
37. Li S, Zhou Y, Dong Y, Ip C. Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Res. 2007;27(5A):3075-3082.
38. Stel AJ, Ten Cate B, Jacobs S, et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol. 2007;178(4): 2287-2295.
39. Amoroso A, Hafsi S, Militello L, et al. Understanding rituximab function and resistance: implications for tailored therapy. Front Biosci. 2011;16:770-782.
40. Müller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99(3):403-413.
41. Müller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998;188(11):2033-2045.
42. Takahashi H, Feuerhake F, Kutok JL, et al. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res. 2006; 12(11 Pt 1):3265-3271.
43. Grønbaek K, Straten PT, Ralfkiaer E, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood. 1998;92(9):3018-3024.
44. Wang X, DeFrances MC, Dai Y, et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell. 2002;9(2):411-421.
45. Mielgo A, van Driel M, Bloem A, Landmann L, Günthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ. 2006;13(3):465-477.
46. Daniluk U, Kerros C, Tao RH, et al. The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells. J Exp Clin Cancer Res. 2012;31(1):69.
47. Kanwar JR, Roy K, Kanwar RK. Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol. 2011;46(6):459-477.
48. Kim JK, Choi KJ, Lee M, Jo MH, Kim S. Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer-and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials. 2012;33(1):207-217.
49. Drecoll E, Gaertner FC, Miederer M, et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS ONE. 2009;4(5):e5715.
50. Fang X, Tan W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res. 2010;43(1):48-57.
51. Hu Q, Gu G, Liu Z, et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials. 2013;34(4):1135-1145.
52. Prickett WM, Van Rite BD, Resasco DE, Harrison RG. Vascular targeted single-walled carbon nanotubes for near-infrared light therapy of cancer. Nanotechnology. 2011;22(45):455101.
53. Fogal V, Sugahara KN, Ruoslahti E, Christian S. Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature. Angiogenesis. 2009;12(1):91-100.
54. Minota S, Jarjour WN, Suzuki N, et al. Autoantibodies to nucleolin in systemic lupus erythematosus and other diseases. J Immunol. 1991;146(7):2249-2252.
55. Qin Z, Lavingia B, Zou Y, Stastny P. Antibodies against nucleolin in recipients of organ transplants. Transplantation. 2011;92(7):829-835.
56. Krust B, El Khoury D, Nondier I, Soundaramourty C, Hovanessian AG. Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type. BMC Cancer. 2011;11:333.
57. Rosenberg JE, Drabkin HA, Lara P, et al. A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (abstract). J Clin Oncol. 2010: suppl; abstract 4590.
58. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358-2365.
59. Rizzieri D, Stockerl-Goldstein K, Wei A, et al. Longterm outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML (abstract). J Clin Oncol. 2010:suppl; abstr 6557.
60. Destouches D, El Khoury D, Hamma-Kourbali Y, et al. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS ONE. 2008;3(6):e2518.
61. El Khoury D, Destouches D, Lengagne R, et al. Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice. BMC Cancer. 2010;10:325.